DOE Patents title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Anticancer therapy


A subject afflicted with a cancer or precancerous condition is treated by administering an agent that increases expression of somatostatin receptors, and a cytotoxic recognition ligand. In an alternative embodiment, somatostatin analogs, which are radiolabeled are used to treat cancer or precancerous conditions.

Issue Date:
Research Org.:
STC.UNM, Albuquerque, NM (United States)
Sponsoring Org.:
OSTI Identifier:
Patent Number(s):
Application Number:
STC.UNM (Albuquerque, NM)
Patent Classifications (CPCs):
DOE Contract Number:  
Resource Type:
Resource Relation:
Patent File Date: 2017 Feb 08
Country of Publication:
United States

Citation Formats

Norenberg, Jeffrey P. Anticancer therapy. United States: N. p., 2019. Web.
Norenberg, Jeffrey P. Anticancer therapy. United States.
Norenberg, Jeffrey P. Tue . "Anticancer therapy". United States.
title = {Anticancer therapy},
author = {Norenberg, Jeffrey P.},
abstractNote = {A subject afflicted with a cancer or precancerous condition is treated by administering an agent that increases expression of somatostatin receptors, and a cytotoxic recognition ligand. In an alternative embodiment, somatostatin analogs, which are radiolabeled are used to treat cancer or precancerous conditions.},
doi = {},
journal = {},
number = ,
volume = ,
place = {United States},
year = {2019},
month = {1}

Works referenced in this record:

Treatment of damaged bone marrow and dosage units therefor
patent, July 1990

Preclinical Evaluation of the α-Particle Generator Nuclide 225Ac for Somatostatin Receptor Radiotherapy of Neuroendocrine Tumors
journal, June 2008

Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues
journal, November 2009

Somatostatin in the central nervous system: Physiology and pathological modifications
journal, January 1986

Peptide Receptors as Molecular Targets for Cancer Diagnosis and Therapy
journal, August 2003

Biochemical and Functional Properties of Somatostatin Receptors
journal, June 1992

Tumor Imaging and Therapy Using Radiolabeled Somatostatin Analogues
journal, July 2009

Long-term toxicity of [177Lu-DOTA0,Tyr3]octreotate in rats
journal, September 2006

Hypothalamic hormones: from neuroendocrinology to cancer therapy
journal, January 1994

Cloning, Functional Expression and Pharmacological Characterization of a Fourth (hSSTR4) and a Fifth (hSSTR5) Human Somatostatin Receptor Subtype
journal, September 1993

RGD (Arg-Gly-Asp) coupled to (neuro)peptides
patent, April 2007

A human somatostatin receptor (SSTR3), located on chromosome 22, displays preferential affinity for somatostatin-14 like peptides
journal, April 1993

Somatostatin analogs for the treatment of cancer
patent, November 2001

Cyclic peptide somatostatin analogs
patent, August 1999

Synthesis and biological activity of highly potent octapeptide analogs of somatostatin.
journal, March 1986

Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines
journal, May 1999

Conformationally constrained backbone cyclized somatostatin analogs
patent, April 2000

Clinical results of long‐term slow‐release lanreotide treatment of acromegaly
journal, April 1997

A potent cyclic hexapeptide analogue of somatostatin
journal, July 1981

In vitro detection of somatostatin receptors in human tumors
journal, September 1992

Bifunctional chelating agents
patent, October 1991

Treatment with 90Y- and 177Lu-DOTATOC in patients with metastatic neuroendocrine tumors
journal, December 2006

Glossary of terms used in medicinal chemistry (IUPAC Recommendations 1998)
journal, January 1998

Experimental facts supporting a red marrow uptake due to radiometal transchelation in 90Y-DOTATOC therapy and relationship to the decrease of platelet counts
journal, February 2011

Conformationally constrained backbone cyclized somatostatin analogs
patent, August 2005

Peptide compounds having improved binding affinity to somatostatin receptors
patent, October 2006

Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin
journal, February 1998

RAPID COMMUNICATION: Human Ovarian Cancers Express Somatostatin Receptors
journal, October 2000

Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney.
journal, January 1992

Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors
journal, April 2008

Anticancer therapy
patent, April 2017

Combined Modality Therapy of Gemcitabine and Radiation
journal, January 2005

Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients
journal, August 1993

Receptor Radionuclide Therapy with 90Y-DOTATOC in Patients with Medullary Thyroid Carcinomas
journal, February 2004

Internalization of [DOTAo,125I-Tyr3]Octreotide by Somatostatin Receptor-Positive Cells In Vitro and In Vivo: Implications for Somatostatin Receptor-Targeted Radio-guided Surgery
journal, January 1999

Targeted radiotherapy for small cell lung cancer using 90Yttrium-DOTATOC, an Yttrium-labelled somatostatin analogue: a pilot trial
journal, September 2004

SMS 201–995: A very potent and selective octapeptide analogue of somatostatin with prolonged action
journal, September 1982

A Comparison of High- Versus Low-Linear Energy Transfer Somatostatin Receptor Targeted Radionuclide Therapy In Vitro
journal, February 2005

Yttrium-90 DOTATOC: first clinical results
journal, October 1999

The Enzyme Ribonucleotide Reductase: Target for Antitumor and Anti-HIV Therapy
journal, January 1997

Nephrotoxicity in Mice After Repeated Imaging Using 111In-Labeled Peptides
journal, May 2010

Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues
journal, December 2005

Somatostatin receptor-targeted radionuclide therapy of tumors: Preclinical and clinical findings
journal, April 2002

A new peptidic somatostatin agonist with high affinity to all five somatostatin receptors
journal, December 2002

Phase I Trial of 90Y-DOTATOC Therapy in Children and Young Adults with Refractory Solid Tumors That Express Somatostatin Receptors
journal, September 2010

Receptor Targeting for Tumor Localisation and Therapy with Radiopeptides
journal, September 2000

Radiolabeled Somatostatin Analog [ 177 Lu-DOTA 0 ,Tyr 3 ]Octreotate in Patients With Endocrine Gastroenteropancreatic Tumors
journal, April 2005

journal, January 1996

Somatostatin Receptor-Based Scintigraphy and Antitumor Treatment--An Expanding Vista?
journal, October 2000

Vapreotide, a new somatostatin analogue in the palliative management of obstructive ileus in advanced cancer
journal, January 1993

patent, July 1997

Therapy using labelled somatostatin analogues: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide
journal, January 2008

Assessment of Hepatic Toxicity from Treatment with 90Y-SMT 487 (OctreoTher™) in Patients with Diffuse Somatostatin Receptor Positive Liver Metastases
journal, August 2003

Somatostatin analogs
patent, March 2002

90Y-DOTA-D-Phe1-Try3- octreotide in therapy of neuroendocrine malignancies
journal, January 2002

Lymphocytic Toxicity in Patients After Peptide-Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE and 90Y-DOTATOC
journal, December 2009

Somatostatin and Its Receptor Family
journal, July 1999

Phase I study of peptide receptor radionuclide therapy with [111In-DTPA0]octreotide: The rotterdam experience
journal, April 2002